ERBB2 and breast cancer: Cytotoxic and targeted chemotherapies including anthracyclines, cyclophosphamide, and trastuzumab targeting human epidermal growth factor receptor 2 (HER2) account for 27% of cardiac dysfunctions, 19% of which is New York Heart Association (NYHA) class III/IV in BC patients [12–15].